drugset / Trial / NCT03757117

Gender-Affirmative Transgender Care to Improve the HIV Treatment Cascade

NCT03757117

NaSingle-groupOpen-labelHealth-services research

Summary

Public health strategies are urgently needed to improve HIV disparities among transgender women, highly burdened by the epidemic globally, including holistic approaches that address those health needs prioritized by the community. To address this urgent need, a three-phase implementation science study of an integrated HIV service delivery model that combined HIV prevention and treatment services with gender-affirming primary medical care for transgender women was implemented in Lima, Peru, supported by peer navigation to improve outcomes across the HIV continuum of care: regular HIV testing for HIV-uninfected participants and linkage to preventive services; and engagement in treatment resulting in viral suppression for HIV-infected participants.

Timeline

Start
2016-10-01
Primary completion
2018-03-31
Completion
2018-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Spironolactone Small molecule 200 mg Oral
Subject estradiol valerate Unknown 4 mg Oral